Structured Review

Corning Life Sciences pyridone 6
Pyridone 6, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pyridone 6/product/Corning Life Sciences
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
pyridone 6 - by Bioz Stars, 2024-07
86/100 stars

Images

pyridone 6  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Tocris pyridone 6
    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor <t>Pyridone</t> <t>6</t> (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Pyridone 6, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyridone 6/product/Tocris
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pyridone 6 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence"

    Article Title: Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence

    Journal: Oncogene

    doi: 10.1038/s41388-024-02973-x

    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Figure Legend Snippet: Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Techniques Used: Luciferase, Activity Assay, Co-Culture Assay, Inhibition, Derivative Assay, Expressing


    Structured Review

    Corning Life Sciences pyridone 6
    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor <t>Pyridone</t> <t>6</t> (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Pyridone 6, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyridone 6/product/Corning Life Sciences
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pyridone 6 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence"

    Article Title: Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence

    Journal: Oncogene

    doi: 10.1038/s41388-024-02973-x

    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Figure Legend Snippet: Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Techniques Used: Luciferase, Activity Assay, Co-Culture Assay, Inhibition, Derivative Assay, Expressing


    Structured Review

    Millipore pyridone 6
    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor <t>Pyridone</t> <t>6</t> (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Pyridone 6, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyridone 6/product/Millipore
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pyridone 6 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence"

    Article Title: Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence

    Journal: Oncogene

    doi: 10.1038/s41388-024-02973-x

    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Figure Legend Snippet: Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Techniques Used: Luciferase, Activity Assay, Co-Culture Assay, Inhibition, Derivative Assay, Expressing


    Structured Review

    Millipore pyridone 6
    Pyridone 6, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyridone 6/product/Millipore
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pyridone 6 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    pyridone 6  (Tocris)


    Bioz Verified Symbol Tocris is a verified supplier
    Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Tocris pyridone 6
    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor <t>Pyridone</t> <t>6</t> (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Pyridone 6, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyridone 6/product/Tocris
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pyridone 6 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence"

    Article Title: Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence

    Journal: Oncogene

    doi: 10.1038/s41388-024-02973-x

    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Figure Legend Snippet: Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Techniques Used: Luciferase, Activity Assay, Co-Culture Assay, Inhibition, Derivative Assay, Expressing

    pyridone 6  (Tocris)


    Bioz Verified Symbol Tocris is a verified supplier
    Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Tocris pyridone 6
    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor <t>Pyridone</t> <t>6</t> (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Pyridone 6, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyridone 6/product/Tocris
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pyridone 6 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence"

    Article Title: Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence

    Journal: Oncogene

    doi: 10.1038/s41388-024-02973-x

    Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
    Figure Legend Snippet: Examples of positive hits from the drug screen showing how the drug dose response affects MCF7 ERE-luciferase activity in mono- or co-cultures with CAF2 cells, as well as viability of both cell types in co-cultures. 4-OH Tamoxifen is shown as an example of a drug that reduce ERE activity ( A ). Drugs that abrogate the reduced luciferase activity induced by CAFs include the topoisomerase II inhibitor etoposide ( B ), the HDAC inhibitor valproic acid ( C ), the CDK4/6 inhibitors palbociclib ( D ) and abemaciclib ( E ), the TGF-β inhibitor TEW-7197 ( F ) and the JAK inhibitor pacritinib ( G ). The left y-axis displays the ER-α activity (as measured by luciferase) of MCF7 cells alone (blue line) or with CAF2 co-culture (red line). The bar graphs represent the viability of MCF7 cells (blue column), or the CAF2 (red column) on the right y-axis. The effect of TGF-β type I receptor inhibition and JAK inhibition was validated through the use of other inhibitors of the TGF-β type I receptor (SB-431542; TGF-βi, 5 µM) ( H ) or pan-JAK inhibitor Pyridone 6 (JAKi, 75 nM) ( I ) on CAF2-mediated reduction of ER-α-activity in MCF7 cells. Pathway activity scores derived from PROGENy demonstrate a significant negative correlation between TGF-β ( J ) and JAK ( K ) signaling pathway activity with the expression of ESR1 in luminal breast cancers included in the TCGA dataset. Error bars: SEM with unpaired ordinary one-away ANOVA, Fisher’s LSD multiple comparisons test: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

    Techniques Used: Luciferase, Activity Assay, Co-Culture Assay, Inhibition, Derivative Assay, Expressing


    Structured Review

    Phenomenex ltd luna c18 2 analytical column
    Luna C18 2 Analytical Column, supplied by Phenomenex ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/luna c18 2 analytical column/product/Phenomenex ltd
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    luna c18 2 analytical column - by Bioz Stars, 2024-07
    86/100 stars

    Images

    18f mk 6577 injection  (GE Healthcare)


    Bioz Verified Symbol GE Healthcare is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    GE Healthcare 18f mk 6577 injection
    18f Mk 6577 Injection, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/18f mk 6577 injection/product/GE Healthcare
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    18f mk 6577 injection - by Bioz Stars, 2024-07
    86/100 stars

    Images


    Structured Review

    Harvard Bioscience 18f mk 6577
    18f Mk 6577, supplied by Harvard Bioscience, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/18f mk 6577/product/Harvard Bioscience
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    18f mk 6577 - by Bioz Stars, 2024-07
    86/100 stars

    Images